Skip to main content

Evidence gap analysis

Strategic analysis of the sufficiency of evidence to obtain reimbursement and HTA approval in Europe and recommendations about evidence generation

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Published HTAs in Q1 2024 in Scotland

In Scotland, the Scottish Health Technology Group (SHTG) develops HTAs and clinical guidelines to support decision-making. The following assessments related to medical procedures or technologies were published in the first quarter of 2024:

  • Artificial intelligence supported clinician review of chest X-rays from patients with suspected lung cancer;
  • An assessment of local anesthetic biopsies of suspicious laryngeal and pharyngeal lesions;
  • Digital prevention program for people at risk of Type 2 diabetes.

The details can be found here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.